Abstract
Identification of specific oncogenic genetic drivers can improve survival in a subset of patients with NSCLC, eligible for modern targeted therapies. Detection of ROS1 rearrangements became standard of diagnostic, but some challenges are under discussion in this setting. We report the first results of large-scale testing in an all-Russian Network for Molecular Diagnostics in cancer patients supported by RUSSCO.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call